LivaNova PLC logo
LivaNova PLC LIVN
$ 63.08 -0.27%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

LivaNova PLC Financial Statements 2011-2025 | LIVN

Annual Financial Statements LivaNova PLC

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.28 B 2.95 B 2.59 B 4.43 B 3.22 B 3.3 B 4.29 B 4.1 B 2.31 B 1.83 B - - - -

Shares

54.2 M 53.9 M 53.5 M 50.6 M 48.6 M 48.3 M 48.5 M 48.2 M 48.9 M 32.7 M - - - -

Historical Prices

42 54.8 48.4 87.4 66.2 75.4 91.5 79.9 45 59.4 - - - -

Net Income

63.2 M 17.5 M -86.2 M -136 M -349 M -155 M -189 M -25.1 M -62.8 M 57.8 M 54.9 M 46.4 M 36.1 M 46.7 M

Revenue

1.25 B 1.15 B 1.02 B 1.04 B 934 M 1.08 B 1.11 B 1.01 B 965 M 292 M 282 M 254 M 219 M 190 M

Cost of Revenue

383 M 382 M 315 M 329 M 339 M 360 M 361 M 353 M 368 M 27.3 M 27.4 M 21.9 M - -

Gross Profit

871 M 771 M 707 M 706 M 595 M 745 M 734 M 652 M 560 M 264 M 255 M 232 M 199 M 167 M

Operating Income

129 M -68.5 M -76.8 M -784 K -274 M -172 M -248 M 96.5 M 33.4 M 88.7 M 80 M 78.3 M - -

Interest Expense

1.01 M -931 K 691 K 50.2 M 40.8 M 15.1 M 9.82 M 7.8 M 10.6 M 21 K 20 K 119 K - -

EBITDA

154 M -43.8 M -54.4 M 23.8 M -245 M -98.2 M -167 M 210 M 117 M 105 M 93.1 M 83 M 65.7 M 51.9 M

Operating Expenses

- - - - - 697 M 648 M 523 M 637 M 167 M 167 M 154 M 138 M 118 M

General and Administrative Expenses

526 M 518 M 469 M 472 M 447 M 507 M 462 M 382 M 357 M - - - - -

All numbers in USD currency

Quarterly Income Statement LivaNova PLC

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

54.6 M 54.6 M 54.4 M 54.3 M 54.4 M 54.2 M 54 M 53.9 M 54 M 53.8 M 53.6 M 53.6 M 53.5 M 53.5 M 53.3 M 53.3 M 51.6 M 48.9 M 48.7 M 48.7 M 48.7 M 48.6 M 48.5 M 48.4 M 48.4 M 48.3 M 48.2 M 48.2 M 48.6 M 48.5 M 48.3 M 48.3 M 48.2 M 48.1 M 48.1 M 48 B 49.1 M 49.1 M 48.9 M 48.9 M 26 M 26 M 26 M - 26.6 M - 26 M - - - 26.7 M - - - - - - - -

Net Income

26.8 M 27.2 M -327 M - 33 M 16.3 M -41.9 M - -7.32 M 1.16 M 7.37 M - -107 M 16.4 M 2.99 M -5.13 M -43.4 M -56.5 M -30.8 M -281 M -14.8 M -89.4 M -88 M -143 M 32.1 M -29.2 M -14.8 M -211 M -7.18 M 15.1 M 13.3 M -112 M 27.8 M 47.5 M 11.3 M -29.8 M -1.57 M 8.96 M -40.4 M -16.9 M -25.1 M -25.1 M 10.5 M 16.5 M 17.3 M 13.5 M 10.5 M - 17.3 M 13.5 M - - - - - - - - -

Revenue

358 M 353 M 317 M - 318 M 319 M 295 M - 286 M 294 M 263 M - 253 M 254 M 240 M 270 M 253 M 264 M 248 M 270 M 240 M 182 M 182 M 288 M 269 M 277 M 251 M 297 M 272 M 287 M 250 M 278 M 251 M 256 M 227 M 250 M 295 M 321 M 287 M 267 M 67.5 M 67.5 M 74.1 M 68.2 M 73.4 M 72 M 74.8 M - 70.1 M 68.9 M - - - - - - - - -

Cost of Revenue

113 M 114 M 96.1 M - 97.1 M 104 M 87.5 M - 84.3 M 88.7 M 89.3 M - 81.7 M 69.8 M 71.7 M - 84.6 M 90.8 M 84.2 M - 92.4 M 65.7 M 142 M - 86.1 M 74.9 M 84.3 M - 94.3 M 92 M 84.6 M - 87.8 M 84 M 80 M - 106 M 131 M 124 M - 9.54 M 9.54 M 7.6 M - 6.77 M - - - - - - - - - - - - - -

Gross Profit

245 M 239 M 221 M - 221 M 215 M 207 M - 202 M 205 M 174 M - 171 M 184 M 168 M 202 M 169 M 172 M 163 M 167 M 148 M 115 M 116 M 205 M 179 M 197 M 164 M 204 M 174 M 194 M 162 M 172 M 162 M 170 M 148 M 125 M 154 M 148 M 132 M 137 M 58 M 58 M 66.5 M 65.5 M 66.7 M 65.6 M 66.5 M - 66.7 M 65.6 M - - - - - - - - -

Operating Income

54 M 54.2 M 48.6 M - 35.6 M 40.2 M 16.2 M - 4.46 M 17.4 M -2.34 M - -132 M 31.8 M 9.5 M 24.8 M 16.4 M -36.3 M -5.7 M -249 M -7.55 M -16.7 M -15.2 M -144 M 25.8 M -29.9 M -20.8 M -276 M -5.76 M 21.6 M 12.5 M 18.9 M 30 M 27.8 M 19.7 M -14.9 M 30.4 M 25 M -9.07 M - -26.4 M -26.4 M 16.7 M - 26.3 M - - - - - - - - - - - - - -

Interest Expense

400 K 200 K -73 K - 275 K 104 K -369 K - 15 M -185 K 13.4 M - 12.7 M 14.4 M 7.84 M - 11.4 M 16.5 M 15.9 M - 14.7 M 5.72 M 10.6 M - 4.77 M 4.05 M 1.66 M - 2.63 M 3.01 M 2.11 M - 1.42 M 1.58 M 2.32 M - 3.5 M 1.98 M 1.19 M - 125 K 22 K 7 K - -7.12 K - - - - - - - - - - - - - -

EBITDA

- - 55 M - - - 22.5 M - - - 3.61 M - -115 M 31.8 M 15.1 M 24.8 M 34.9 M -36.3 M 381 K -249 M 14.7 M -16.7 M -1.64 M -144 M 48.9 M -14.6 M -13.2 M -276 M 19.2 M 38.2 M 20.9 M 18.9 M 57.9 M 45.8 M 28.5 M -14.9 M 52.9 M 43.1 M 14.5 M - -22.8 M -24.9 M 18.7 M - 26.3 M - 2.1 M - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 180 M 172 M 150 M - 132 M 142 M 128 M - 165 M 168 M 199 M - 84.3 M 84.3 M 49.8 M - 40.4 M - - - - - - - - - - - - - -

General and Administrative Expenses

139 M 138 M 134 M - 127 M 125 M 130 M - 135 M 126 M 124 M - 115 M 116 M 119 M - 109 M 123 M 116 M - 104 M 103 M 228 M - 123 M 127 M 126 M - 115 M 123 M 104 M - 97.2 M 94.3 M 87.3 M - 109 M 121 M 116 M - 41.2 M 41.2 M 29.7 M - 29.6 M - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements LivaNova PLC LIVN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting LivaNova PLC plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 96.13 0.04 % $ 141 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.6 - $ 125 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 301.75 0.24 % $ 8.51 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 48.12 0.21 % $ 7.17 K usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 124.81 0.22 % $ 217 B usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 2.97 4.58 % $ 111 M franceFrance
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.47 0.7 % $ 1.15 B israelIsrael
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.14 3.64 % $ 18.4 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
IRadimed Corporation IRadimed Corporation
IRMD
$ 97.06 0.48 % $ 1.23 B usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 9.54 - $ 685 M israelIsrael
LENSAR LENSAR
LNSR
$ 12.01 -0.08 % $ 138 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Align Technology Align Technology
ALGN
$ 157.84 0.69 % $ 11.8 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.86 0.43 % $ 88.4 M usaUSA
Myomo Myomo
MYO
$ 1.02 12.09 % $ 7.19 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.49 0.84 % $ 392 M usaUSA
FONAR Corporation FONAR Corporation
FONR
$ 14.53 0.07 % $ 95.2 M usaUSA
AxoGen AxoGen
AXGN
$ 32.64 -0.61 % $ 1.44 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 40.17 1.34 % $ 1.24 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 17.41 0.75 % $ 402 M usaUSA
Globus Medical Globus Medical
GMED
$ 88.43 -0.38 % $ 12 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 12.66 0.56 % $ 975 M usaUSA